BPC-157 vs CJC-1295: Recovery vs Growth Hormone
Here is how these two compounds compare — based on published research, not marketing claims.
BPC-157
212
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
CJC-1295
27
Indexed Studies
Animal Studies
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
People compare these because both appear in peptide therapy protocols. But they do completely different things. BPC-157 is a tissue repair peptide studied for tendons, gut lining, and wound healing. CJC-1295 is a growth hormone-releasing hormone analog that tells your pituitary to produce more GH. Choosing between them is like choosing between a bandage and a vitamin — they solve different problems.
Key Differences
| Attribute | BPC-157 | CJC-1295 |
|---|---|---|
| Evidence Level | Human Trials | Animal Studies |
| Category | Body Protection Compound | GHRH Analog |
| Human Data | Two pilot studies plus over 200 animal studies. PSI rates L3. | A few human pharmacokinetic studies. Less extensive than BPC-157. |
| Safety Profile | Extensive animal safety data. Two human pilot studies (2024-2025) with no serious adverse events. Not FDA-approved. | Limited but favorable human safety data. Side effects include water retention, numbness, and injection site reactions. |
| Key Limitations | Most research from one group. Human data is early-stage. | Fewer human trials. DAC version creates sustained (not pulsatile) GH elevation. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
BPC-157
Promotes blood vessel formation and growth factor expression at injury sites. Targets the repair process directly — angiogenesis, collagen deposition, nitric oxide regulation.
CJC-1295
Mimics growth hormone-releasing hormone to stimulate the pituitary gland. The DAC version extends the half-life to days, producing sustained GH elevation rather than natural pulsatile release.
Completely different biological targets. BPC-157 works locally at injury sites — sending repair signals to damaged tissue. CJC-1295 works systemically through the pituitary — raising growth hormone levels throughout the body. BPC-157 is a targeted repair tool. CJC-1295 is a systemic hormone optimizer.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 239 indexed studies. Here are the key findings.
BPC-157 is L3 with over 200 studies and human pilot data. CJC-1295 is L2 with fewer publications and limited human pharmacokinetic studies. For tissue repair, BPC-157 has significantly more relevant evidence.
For specific tissue injury (tendon, gut, muscle) — BPC-157 has directly relevant research.
For growth hormone optimization and body composition — CJC-1295 is the appropriate compound.
For post-injury recovery with GH support — some practitioners combine them, targeting different systems.
These are not interchangeable. Choosing one over the other depends entirely on the goal.
Key Limitations
- •No head-to-head comparison exists.
- •They target different biological systems, making direct comparison limited.
- •Neither has Phase III clinical trial data.
- •Combining them is common in practice but unstudied in controlled research.
PSI Verdict
SUPPORTED BY EVIDENCE
BPC-157 promotes tissue repair through angiogenesis and growth factor signaling, with over 200 published studies. CJC-1295 elevates growth hormone and IGF-1 levels in humans through GHRH receptor activation.
NOT YET ESTABLISHED
Whether combining BPC-157 and CJC-1295 produces additive benefits has not been studied. Long-term human outcome data is incomplete for both compounds.
CONFIDENCE LEVEL
These serve different purposes. Comparing them for the same goal does not make sense. If the question is tissue repair, BPC-157 is the researched option. If the question is GH elevation, CJC-1295 is the relevant compound.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
BPC-157
"BPC-157 healed my gut issues in two weeks"Plausible but unproven in humans
"BPC-157 fixed my tendon injury faster than anything"Plausible but unproven in humans
"BPC-157 is completely safe with no side effects"Insufficient evidence
CJC-1295
"CJC-1295 with DAC gives you sustained growth hormone elevation for days"Supported by published data
"Stacking CJC-1295 with ipamorelin is the gold standard for GH optimization"Plausible but unproven
"It made me retain water and feel bloated"Supported by published data
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
BPC-157
Extensive animal safety data. Two human pilot studies (2024-2025) with no serious adverse events. Not FDA-approved.
CJC-1295
Limited but favorable human safety data. Side effects include water retention, numbness, and injection site reactions.
BPC-157 has more published safety data. CJC-1295 has fewer studies but no serious safety signals. Both require medical supervision. Neither is FDA-approved.
WHAT THE RESEARCH SUGGESTS
These are not competing compounds. BPC-157 for tissue repair. CJC-1295 for growth hormone. The comparison exists because both appear in peptide protocols, not because they serve the same purpose.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.